TLDR
- ARK ETFs purchased 119,118 AMD shares worth approximately $11.4 million
- ARK sold 354,188 shares of CRISPR Therapeutics valued at over $13.2 million
- Wood also bought shares of Shopify and Intellia Therapeutics in recent trading
- AMD is expected to report 30% revenue growth in its upcoming earnings release
- Despite strong fundamentals, AMD stock has fallen 40% over the past year
Cathie Wood’s ARK Invest has made several major stock moves in late April 2025, focusing on semiconductor and healthcare sectors while divesting from certain biotech and defense holdings. The trades come as Wood’s funds have outperformed the broader market, with her flagship ETF gaining 6% over the past month while the market remained flat.
ARK made its largest purchase in Advanced Micro Devices (AMD), acquiring 119,118 shares valued at approximately $11.4 million. The shares were distributed between the ARKK and ARKW ETFs, with the majority going to ARKK. This purchase shows ARK’s continued confidence in the semiconductor industry.
The purchase comes just days before AMD’s first-quarter earnings report, which analysts expect to show 30% revenue growth to $7.1 billion. This would mark AMD’s strongest year-over-year growth in nearly three years and its fourth consecutive quarter of accelerating revenue gains. Earnings are projected to jump even higher, with a 52% increase to $0.94 per share.
Despite these positive fundamentals, AMD’s stock has fallen 40% over the past year. The company recently announced it will take an $800 million charge related to the banning of its MI308X processor in China. This charge is not factored into the upcoming financial report.
AMD stock is currently trading at 22 times this year’s estimated earnings and 16 times next year’s projections. The company’s growth is largely driven by surging demand for AI chips and data center buildouts.
Strategic Portfolio Rebalancing
While adding to its AMD position, ARK made several sales, with CRISPR Therapeutics (CRSP) seeing the largest reduction. ARK sold 354,188 CRSP shares through its ARKK ETF, a transaction worth over $13.2 million. This continues a recent trend of ARK reducing its CRISPR holdings.
Other sales included 83,126 shares of defense contractor Kratos Defense and Security Solutions (KTOS) worth nearly $2.9 million, as well as smaller positions in Palantir Technologies (PLTR) and Roblox Corp (RBLX).
Wood also purchased shares of Shopify (SHOP), which is scheduled to report earnings shortly after AMD. Analysts expect Shopify to post 25% revenue growth and 30% earnings growth. The e-commerce platform provider has maintained revenue growth above 20% annually for more than a decade.
Despite Shopify’s consistent performance, nearly a dozen analysts have recently lowered their price targets due to concerns about weakening retail trends amid declining consumer confidence. Shopify has helped businesses sell $1 trillion through its platform since 2006, with half of those transactions occurring in just the last two years.
ARK also invested in Intellia Therapeutics, a gene-editing stock that recently received an upgrade from Wolfe Research analyst Andy Chen. Chen upgraded the stock to Outperform, noting that despite a market cap approaching $850 million, its strong cash position drops its enterprise value below $200 million.
In the healthcare sector, ARK’s ARKK ETF purchased 118,730 shares of Natera Inc (NTRA) and 345,607 shares of Pacific Biosciences of California (PACB), with the latter transaction amounting to just over $383,000.
Smaller trades included purchases of Blade Air Mobility (BLDE), Personalis Inc (PSNL), Symbotic Inc (SYM), and 10X Genomics (TXG), with the latter seeing an addition of 184,619 shares valued at approximately $1.55 million.
ARK also purchased 6,933 shares of heavy machinery manufacturer Caterpillar (CAT) through its ARKQ ETF, a trade worth more than $2.1 million. Additionally, the ARKW ETF acquired 25,571 shares of software development platform GitLab (GTLB) for approximately $1.2 million.
These moves reflect Wood’s strategic repositioning of ARK’s portfolio, with clear focus on technology and healthcare sectors, particularly genomics, while reducing exposure to certain biotech and defense stocks.
AMD will report its first-quarter results next Tuesday after market close, followed by Shopify’s earnings report two days later.
